Nectar Lifesciences Limited

NSE NECLIFE.NS

Nectar Lifesciences Limited Free Cash Flow for the year ending March 31, 2024: USD 23.41 M

Nectar Lifesciences Limited Free Cash Flow is USD 23.41 M for the year ending March 31, 2024, a 85.74% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Nectar Lifesciences Limited Free Cash Flow for the year ending March 31, 2023 was USD 12.60 M, a 36.65% change year over year.
  • Nectar Lifesciences Limited Free Cash Flow for the year ending March 31, 2022 was USD 9.22 M, a 784.83% change year over year.
  • Nectar Lifesciences Limited Free Cash Flow for the year ending March 31, 2021 was USD -1.35 M, a -104.41% change year over year.
  • Nectar Lifesciences Limited Free Cash Flow for the year ending March 31, 2020 was USD 30.55 M, a 5.55% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
SV Wall Street
NSE: NECLIFE.NS

Nectar Lifesciences Limited

CEO Mr. Amit Chadah
IPO Date July 18, 2005
Location India
Headquarters SCO 38-39
Employees 1,686
Sector Health Care
Industries
Description

Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.

Similar companies

KOPRAN.NS

Kopran Limited

USD 2.10

-2.71%

MOREPENLAB.NS

Morepen Laboratories Limited

USD 0.75

4.08%

SUVEN.NS

Suven Life Sciences Limited

USD 1.48

10.54%

MARKSANS.NS

Marksans Pharma Limited

USD 2.78

0.16%

StockViz Staff

February 1, 2025

Any question? Send us an email